CMV-pp65-495_503
Cytomegalovirus pp65 peptide epitope NLVPMVATV (aa 495-503)
NLVPMVATV Amino Acids · MW: 975.2
Amino Acids
NLVPMVATV
Molecular Weight
975.2
Half-life
minutes-hours
Research Score
4.4
Studies
93
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is CMV-pp65-495_503?
A dominant HLA-A*0201 CMV epitope widely used in therapeutic vaccine and immune-monitoring studies. It is especially valuable as a robust viral antigen for generating strong CD8+ T-cell responses.
Key Benefits & Mechanisms
highly immunodominant viral target
rapid recall CD8+ responses
useful positive-control antigen
Research Summary
CMV pp65 495-503 is one of the most widely documented HLA-A2 epitopes in human immunology and vaccine research. Peptide-based formats have been used to boost CMV-specific cellular immunity, including in immunocompromised settings.
Related Peptides
PADRE
Pan HLA-DR-binding helper T-cell epitope
PADRE is a synthetic promiscuous CD4+ helper T-cell epitope designed to bind many HLA-DR alleles. It is widely used in peptide vaccine research to improve helper T-cell priming and strengthen responses to linked antigens.
Vaccine PeptidesSIINFEKL
Ovalbumin 257-264 epitope (SIINFEKL)
SIINFEKL is a classic MHC class I epitope derived from chicken ovalbumin. It is one of the most widely used model peptides for studying antigen presentation, cytotoxic T-cell priming, and peptide vaccine platforms.
Vaccine PeptidesAAGIGILTV
MART-1/Melan-A 26-35 epitope
AAGIGILTV is a well-known HLA-A2-restricted epitope from the melanocyte differentiation antigen MART-1/Melan-A. It has been studied in melanoma vaccine research to generate antigen-specific T-cell responses against tumor cells.
Vaccine PeptidesHPV16 E7(11-20)
Human papillomavirus type 16 E7 11-20 epitope
HPV16 E7(11-20) is a documented cytotoxic T-cell epitope derived from the HPV16 E7 oncoprotein. It has been used in therapeutic HPV vaccine research to stimulate epitope-specific cellular immunity.
Vaccine Peptides